头孢曲松+舒巴坦+乙二胺四乙酸成功治疗泌尿道感染：一种节约青霉烯类药物方法的病例报告
Successful Management of Urosepsis with Ceftriaxone+Sulbactam+EDTA: A Case Report of Penem Sparing Approach.
作者信息
Bery Amit, Sodhi Candy, Bhanot Rishu
机构信息
Consultant, Department of Internal Medicine, DMC, Ludhiana, Punjab, India.
Consultant, Department of Physiology, CMC, Ludhiana, Punjab, India.
出版信息
J Clin Diagn Res. 2017 Sep;11(9):OD18-OD19. doi: 10.7860/JCDR/2017/29146.10661. Epub 2017 Sep 1.
Abstract
Over the past decade, the Anti-Microbial Resistance (AMR) among members of Enterobacteriaceae family is on rise mainly due to rapid spread of strains producing Extended-Spectrum Beta-Lactamases (ESBLs) and Metallo Beta-Lactamases (MBLs). Hence, the choice of drugs available for these resistant strains is diminishing and their treatment is becoming more challenging. This is a case of complicated Urinary Tract Infection (cUTI) due to ESBL producing leading to septic shock which was successfully managed with Antibiotic Adjuvant Entity (AAE), a combination of ceftriaxone+sulbactam+EDTA.
摘要
在过去十年中，肠杆菌科成员中的抗菌药物耐药性（AMR）呈上升趋势，主要原因是产超广谱β-内酰胺酶（ESBLs）和金属β-内酰胺酶（MBLs）菌株的迅速传播。因此，可用于这些耐药菌株的药物选择正在减少，对它们的治疗也变得更具挑战性。这是一例由产ESBLs导致的复杂性尿路感染（cUTI），进而引发了感染性休克，使用抗生素辅助实体（AAE），即头孢曲松+舒巴坦+乙二胺四乙酸的组合，成功进行了治疗。
相似文献
1
Successful Management of Urosepsis with Ceftriaxone+Sulbactam+EDTA: A Case Report of Penem Sparing Approach.
J Clin Diagn Res. 2017 Sep;11(9):OD18-OD19. doi: 10.7860/JCDR/2017/29146.10661. Epub 2017 Sep 1.
2
A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital.
J Clin Diagn Res. 2015 Nov;9(11):FC29-32. doi: 10.7860/JCDR/2015/14129.6840. Epub 2015 Nov 1.
3
Phenotypic detection of AmpC β-lactamases, extended-spectrum β-lactamases and metallo-β-lactamases in Enterobacteriaceae using a resazurin microtitre assay with inhibitor-based methods.
J Med Microbiol. 2016 Oct;65(10):1079-1087. doi: 10.1099/jmm.0.000326. Epub 2016 Aug 1.
4
Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.
Drugs. 2003;63(4):353-65. doi: 10.2165/00003495-200363040-00002.
5
Extended-spectrum beta-lactamases (ESbLs): characterization, epidemiology and detection.
Crit Rev Microbiol. 2004;30(1):25-32. doi: 10.1080/10408410490266429.
6
Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
J Antimicrob Chemother. 2004 Apr;53(4):616-9. doi: 10.1093/jac/dkh140. Epub 2004 Feb 25.
7
Antibiotic/adjuvant combinations (ceftriaxone + sulbactam + adjuvant disodium edetate) as an alternative empiric therapy for the treatment of nosocomial infections: Results of a retrospective study.
Indian J Cancer. 2017 Oct-Dec;54(4):685-690. doi: 10.4103/ijc.IJC_364_17.
8
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
J Antimicrob Chemother. 2004 Jun;53(6):1090-4. doi: 10.1093/jac/dkh218. Epub 2004 Apr 29.
9
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
J Antimicrob Chemother. 2006 Apr;57(4):780-3. doi: 10.1093/jac/dkl035. Epub 2006 Feb 21.
10
[Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
Med Dosw Mikrobiol. 2012;64(4):285-95.
本文引用的文献
1
Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Braz J Infect Dis. 2017 Jul-Aug;21(4):408-417. doi: 10.1016/j.bjid.2017.02.007. Epub 2017 Apr 1.
2
A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital.
J Clin Diagn Res. 2015 Nov;9(11):FC29-32. doi: 10.7860/JCDR/2015/14129.6840. Epub 2015 Nov 1.
3
Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal.
Antimicrob Resist Infect Control. 2015 May 1;4:15. doi: 10.1186/s13756-015-0059-2. eCollection 2015.
4
Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.
Diabetes Metab Syndr Obes. 2015 Feb 26;8:129-36. doi: 10.2147/DMSO.S51792. eCollection 2015.
5
The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
J Assoc Physicians India. 2012 Aug;60:28-30.
6
Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.
Dan Med Bull. 2011 Apr;58(4):B4187.
7
Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria.
J Antimicrob Chemother. 2010 Nov;65 Suppl 3:iii25-33. doi: 10.1093/jac/dkq298.
8
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.
Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10.
9
Incidence and antibiotic prescription rates for common infections in patients with diabetes in primary care over the years 1995 to 2003.
Int J Infect Dis. 2009 Nov;13(6):e344-51. doi: 10.1016/j.ijid.2008.12.003. Epub 2009 Feb 8.
Zotero 插件